(VIANEWS) – Shares of OXURION (BEL 20: OXUR.BR) fell by a staggering 16.67% in 5 sessions from €0.01 to €0.01 at 02:25 EST on Monday, after four sequential sessions in a row of losses. BEL 20 is dropping 0.86% to €3,626.44, after three consecutive sessions in a row of losses.
OXURION’s last close was €0.01, 99.34% below its 52-week high of €1.55.
About OXURION
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Earnings Per Share
As for profitability, OXURION has a trailing twelve months EPS of €-0.732.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -694.15%.
Volume
Today’s last reported volume for OXURION is 25034833 which is 91.55% below its average volume of 26586700.
Yearly Top and Bottom Value
OXURION’s stock is valued at €0.01 at 02:25 EST, under its 52-week low of €0.01.
More news about OXURION (OXUR.BR).
